- State-of-the-art facility designed to foster drug delivery -
MADISON, Wis. and NUTLEY, N.J., April 23 /PRNewswire/ -- Today, Roche Madison Inc. officially opened the doors to a new state-of-the-art facility with chemistry and biology labs at the University of Wisconsin Research Park in Madison. Part of the global RNA Therapeutics group within Roche, the group's research focuses on the discovery and development of innovative nucleic acid based technologies, including a proprietary RNAi (Ribonucleic Acid interference) delivery platform. RNAi - a natural mechanism that the body uses to 'silence' certain genes - represents a potential whole new class of therapeutics for difficult to treat diseases. The site currently has a 45-member staff and plans to hire additional staff during the next six to 12 months as part of its planned expansion.
In 2008, Roche purchased Mirus Bio Corporation, a leader in the fields of RNA interference and gene therapy, which became Roche Madison. "We are very pleased to be a vital part of the Roche RNA Therapeutics program and our new facilities will help ensure that we can continue to develop our technology in the most advantageous manner for targeted drug delivery," said Jim Hagstrom, vice president, Operations, Roche Madison. "As one of the few pharmaceutical sites in the state, we look forward to remaining a vital part of the Madison landscape and to finding innovative ways of getting RNAi therapeutics into specific disease targets to benefit patients."
"The presence of the new Roche research site within the University of Wisconsin Research Park represents a win/win situation for both Roche employees and for the Madison economy overall - and it further validates that the high quality research being performed by the Madison scientific community is being recognized by the world's leaPage: 1 2 3 Related biology technology :1
. BioDuro and Roche Expand Strategic Collaboration to Provide Drug Discovery Services2
. Roche to Introduce New LightCycler(R) MRSA Advanced Test in the EU3
. Roche Completes Tender Offer for Genentech4
. Roche and Genentech Reach a Friendly Agreement to Combine the Two Organizations and Create a Leader in Healthcare Innovation5
. SD Canada Announces CE Mark for ThyroChek(R) Adult and NeoNatal Tests6
. Micromet Adds Former Head of Roche Oncology Kapil Dhingra, MD to Board of Directors7
. Roche Intends to Commence Tender Offer to Acquire All Shares of Genentech for US$ 86.50 Per Share in Cash8
. Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients9
. Roche Purchases Shares in Tender Offer For Memory Pharmaceuticals Corp.10
. Axial Biotech Appoints Retired Roche Diagnostics Executive to Board11
. InformationWeek Puts Roche Diagnostics on Top 500 Innovative Tech Users List